Soligenix, Inc. announced on September 26 2025 that it has priced a public offering of 5,555,560 shares of common stock and an equal number of warrants to purchase shares at a combined price of $1.35 per share. The offering is expected to close on or about September 29 2025, subject to customary closing conditions, and will raise approximately $7.5 million in gross proceeds before fees and expenses.
The company plans to use the net proceeds to fund research and development and commercialization activities, working capital, and general corporate purposes. This financing will support the development of its HyBryte™ photodynamic therapy platform, its Innate Defense Regulator (IDR) programs, and its ThermoVax® vaccine initiatives, all of which are in late‑stage development or pre‑clinical stages.
By raising additional capital, Soligenix extends its cash runway beyond the current projected Q1 2026 horizon, providing the liquidity needed to advance its pipeline and pursue strategic partnerships. The infusion of funds is a significant step toward achieving regulatory approvals and potential commercialization of its rare‑disease therapies, thereby enhancing the company’s long‑term growth prospects.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.